
The relative effectiveness and safety profile of the treatments with marketing authorization for zzso multiple sclerosis zzso are not well known because zzso controlled trials with head-to-head comparisons between these treatments do not zzso Thus, a network of zzso zzso was performed using four clinical zzso zzso free of zzso zzso without disease zzso zzso without zzso zzso and zzso with adverse zzso 

zzso controlled trials zzso on zzso were systematically searched in zzso and Cochrane Central Register of Controlled zzso The network analysis performed zzso comparisons between the marketed treatments zzso zzso zzso zzso zzso zzso zzso zzso zzso 7 zzso zzso 14 zzso zzso 20 zzso zzso 300 zzso zzso zzso zzso and zzso 12 zzso using direct and indirect zzso 

The analysis included 48 articles, involving 20 455 patients with zzso The direct analysis showed better response for more than one outcome for zzso compared with zzso zzso free of zzso and zzso without zzso zzso and for zzso compared with zzso zzso without disease zzso and zzso without zzso zzso The indirect analysis indicated that zzso may have better relative effectiveness compared with the other treatments for two zzso zzso free of zzso and zzso without zzso zzso Regarding zzso with adverse zzso no data were available for all comparisons to make fair zzso 

This was an attempt, for the first time, to compare the efficacy and safety profile of existing approved treatments for zzso zzso Although some treatments have shown better response, the results of the network analysis should be interpreted with caution because of the lack of zzso with head-to-head comparisons between zzso 

